본문 바로가기
KERD
논문KCI 등재

COVID-19 Drug Development

김승택
한국미생물·생명공학회 (The Korean Society For Microbiology And Biotechnology)|2022.01|Journal of Microbiology and Biotechnology|제32권 제1호|pp. 1-5|DOI 10.4014/jmb.2110.10029

2

조회

0

다운로드

3

인용

0

참고문헌

키워드

COVID-19SARS-CoV-2monoclonal antibodydrug repurposingconvalescent plasma
주제분류생물학

초록

Diagnostics, vaccines, and drugs are indispensable tools and control measures employed to overcome infectious diseases such as coronavirus disease 2019 (COVID-19). Diagnostic tools based on RT-PCR were developed early in the COVID-19 pandemic and were urgently required for quarantine (testing, tracing and isolation). Vaccines such as mRNA vaccines and virus-vectored vaccines were also successfully developed using new platform technologies within one year after identifying severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as the causative agent of COVID-19. Drug development has been conducted in various ways including drug repurposing, convalescent plasma therapy, and monoclonal antibody development. Among the above efforts, this review examines COVID-19 drug development along with the related and upcoming challenges.

Abstract

Diagnostics, vaccines, and drugs are indispensable tools and control measures employed to overcome infectious diseases such as coronavirus disease 2019 (COVID-19). Diagnostic tools based on RT-PCR were developed early in the COVID-19 pandemic and were urgently required for quarantine (testing, tracing and isolation). Vaccines such as mRNA vaccines and virus-vectored vaccines were also successfully developed using new platform technologies within one year after identifying severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as the causative agent of COVID-19. Drug development has been conducted in various ways including drug repurposing, convalescent plasma therapy, and monoclonal antibody development. Among the above efforts, this review examines COVID-19 drug development along with the related and upcoming challenges.

참고문헌 (36)

  1. Zhou P, "A pneumonia outbreak associated with a new coronavirus of probable bat origin", Nature, 579, pp.270~273 (2020)
  2. "Track the Coronavirus Outbreak on Johns Hopkins Live Dashboard"[URL]
  3. Hu B, "Characteristics of SARS-CoV-2 and COVID-19", Nat. Rev. Microbiol, 19, pp.141~154 (2021)
  4. Hoffmann M, "SARS-CoV-2 cell entry depends on ACE2and TMPRSS2 and is blocked by a clinically proven protease inhibitor", Cell, 181, pp.271~280 (2020)
  5. V’kovski P, "Coronavirus biology and replication : implications for SARS-CoV-2", Nat. Rev. Microbiol, 19, pp.155~170 (2021)
  6. Griffin DO, "The importance of understanding the stages of COVID-19 in treatment and trials", AIDS Rev, 23, pp.40~47 (2021)
  7. Sahu AK, "Steroids use in non-oxygen requiring COVID-19 patients : a systematic review and meta-analysis", QJM, 114, pp.455~463 (2021)
  8. Ashburn TT, "Drug repositioning : identifying and developing new uses for existing drugs", Nat. Rev. Drug Discov, 3, pp.673~683 (2004)
  9. Sheahan TP, "Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses", Sci. Transl. Med, 9, pp.3653~ (2017)
  10. Geleris J, "Observational study of hydroxychloroquine in hospitalized patients with Covid-19", N. Engl. J. Med, 382, pp.2411~2418 (2020)
  11. Borba MGS, "Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)infection", JAMA Netw. Open, 3, pp.208857~ (2020)
  12. Cao B, "A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19", N. Engl. J. Med, 382, pp.1787~1799 (2020)
  13. James H McMahon, "Remdesivir for the treatment of Covid-19-preliminary report", N. Engl. J. Med, 383, pp.992~993 (2020)
  14. WHO Solidarity Trial Consortium, "Repurposed antiviral drugs for Covid-19-interim WHO solidarity trial results", N. Engl. J. Med, 384, pp.497~511 (2021)
  15. "Significantly Reduced Risk of Hospitalization in High-Risk Patients with COVID-19"[URL]
  16. Group TRC, "Dexamethasone in hospitalized patients with Covid-19", N. Engl. J. Med, 384, pp.693~704 (2021)
  17. RECOVERY Collaborative Group, "Tocilizumab in patients admitted to hospital with COVID-19(RECOVERY) : a randomised, controlled, open-label, platform trial", Lancet(London, England), 397, pp.1637~1645 (2021)
  18. Marconi VC, "Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19(COV-BARRIER) : a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial", Lancet Respir. Med, 9, pp.1407~1418 (2021)
  19. Jeon S, "Identification of antiviral drug candidates against SARS-CoV-2 from FDAapproved drugs", Antimicrob. Agents Chemother, 64, pp.00819~00820 (2020)
  20. Hoffmann M, "Nafamostat mesylate blocks activation of SARS-CoV-2 : new treatment option for COVID-19", Antimicrob. Agents Chemother, 64, pp.00754~00720 (2020)
  21. Yamamoto M, "The anticoagulant nafamostat potently inhibits SARS-CoV-2 S protein-mediated fusion in a cell fusion assay system and viral infection in vitro in a cell-typedependent manner", Viruses, 12, pp.629~ (2020)
  22. Ko M, "Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells", J. Med. Virol, 93, pp.1403~1408 (2021)
  23. Kumar S, "Current status of therapeutic monoclonal antibodies against SARS-CoV-2", PLoS Pathog, 17, pp.1009885~ (2021)
  24. Peter Chen, "SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19", New England Journal of Medicine, 384(3), pp.229~237 (2021), Massachusetts Medical Society[DOI]
  25. Gottlieb RL, "Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19", JAMA, 325, pp.632~ (2021)
  26. David M. Weinreich, "REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19", New England Journal of Medicine, 384(3), pp.238~251 (2021), Massachusetts Medical Society[DOI]
  27. Anil Gupta, "Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab", New England Journal of Medicine, 385(21), pp.1941~1950 (2021), Massachusetts Medical Society[DOI]
  28. Korley FK, "Early convalescent plasma for highrisk outpatients with Covid-19", N. Engl. J. Med, 385, pp.1951~1960 (2021)
  29. "Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study"[URL]
  30. Reynard O, "Identification of a new ribonucleoside inihibitor of Ebola virus replication", Viruses, 7, pp.6233~6240 (2015)
  31. Nadya Urakova, "β-d-N4-Hydroxycytidine is a potent anti-alphavirus compound that induces a high level of mutations in the viral genome", Journal of Virology, 92(3) (2018), American Society for Microbiology[DOI]
  32. Toots M, "Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia", Sci. Transl. Med, 11, pp.5866~ (2019)
  33. Maria L. Agostini, "Small-Molecule Antiviral β- <scp>d<", scp> - <i>N<, sup> -Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance, pp.Journal of Virology, 2019[DOI]
  34. "Covid-19 Antiviral Efforts"[URL]
  35. De Clercq E, "Approved antiviral drugs over the past 50 Years", Clin. Microbiol. Rev, 29, pp.695~747 (2016)
  36. Menachery VD, "A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence", Nat. Med, 21, pp.1508~1513 (2015)

관련 논문AI추천

COVID-19 Antiviral and Treatment Candidates: Current Status김다정, 김정기, 김지연, 박성규, Españo Erica대한면역학회 · Immune Network2021 · 제21권 제1호COVID-19: an update on diagnostic and therapeutic approachesAhmed Abdal Dayem, Balachandar Vellingiri, Kaavya Jayaramayya, Mahalaxmi Iyer, Mohana Devi Subramaniam, Soo Bin Lee, Ssang-Goo Cho생화학분자생물학회 · BMB Reports2020 · 제53권 제4호COVID-19 Therapeutics: An Update on Effective Treatments Against Infection With SARS-CoV-2 Variants김정기, 송영천, 이종길, Españo Erica, Kim Sang-Hyun, Padasas Bill Thaddeus대한면역학회 · Immune Network2023 · 제23권 제2호Advancements in Antiviral Drug Development: Comprehensive Insights into Design Strategies and Mechanisms Targeting Key Viral ProteinsCheng Wang, Hangyu Wang, Hongyan Wang, Jie Shen, Kangning Han, Linmiao Wei, Panpan Li, Shuai Wang, Yichen Shi한국미생물·생명공학회 · Journal of Microbiology and Biotechnology2024 · 제34권 제7호Current Status of COVID-19 Vaccine Development: Focusing on Antigen Design and Clinical Trials on Later Stages김두진, 김창웅, 서상환, 이푸름대한면역학회 · Immune Network2021 · 제21권 제1호Ongoing Clinical Trials of Vaccines to Fight against COVID-19 Pandemic이상수, Bhattacharya Manojit, Chakraborty Chiranjib, Saha Rudra P., SHARMA ASHISH RANJAN, Sharma Garima대한면역학회 · Immune Network2021 · 제21권 제1호

이 간행물의 다른 논문 (14건)

A Brucella Omp16 Conditional Deletion Strain Is Attenuated in BALB/c MiceWang Aihua, Jin Yaping, Zhou Dong, Zhang Guangdong, Li Junmei, Zheng Weifang, Fang Jiaoyang, Zhi Feijiepp. 6-14A Newly Synthesized Flavone from Luteolin Escapes from COMT-Catalyzed Methylation and Inhibits Lipopolysaccharide-Induced Inflammation in RAW264.7 Macrophages via JNK, p38 and NF-κB Signaling PathwaysSun Zhi-qin, Xin Yang, Ye Lin, Wu Zhi-yuan, Sun Hai-jian, Huang De-jianpp. 15-26Novel Polyhydroxybutyrate-Degrading Activity of the Microbulbifer Genus as Confirmed by Microbulbifer sp. SOL03 from the Marine Environment양영헌, Ham Sion, Suha Min Ju, Kim Sang Hyun, Gurav Ranjit, Lee Hong-Ju, Cho Jang Yeon, Park Sol Lee, BHATIA SHASHI KANT, Kim Su Hyun, Park Kyungmoon, Park See-Hyoung, 김윤곤pp. 27-36Myricetin Disturbs the Cell Wall Integrity and Increases the Membrane Permeability of Candida albicans이흥식, 김연희pp. 37-45In Vitro and In Vivo Anti-Clostridioides difficile Effect of a Probiotic Bacillus amyloliquefaciens StrainKim Sukyung, Islam Md Imtiazul, Seo Hoonhee, Redwan Asma, Lee Saebim, Siddiquee Mashuk, 송호연pp. 46-55
원문 보기